Brainstorm Cell Therapeutics Investor Presentation — March 2018

Document content

BrainStorm Cell TherapeuticsNASDAQ: BCLIMarch 22, 2018

Forward Looking StatementStatements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital,dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.2בס"ד

Brainstorm At-A-GlanceCLINICAL STAGE BIOTECHNOLOGY COMPANYADVANCED STAGE CLINICAL PROGRAMSLARGE ADDRESSABLE MARKETSPotential to be first-in-class autologous stem cell therapy for ALS and other neurodegenerative diseasesExperienced US management team; R&D in IsraelRobust IP portfolioRepeat Dose Phase 3 ALS trial fully enrolledRepeat Dose Phase 2 Progressive MS Trial actively enrollingRobust Phase 2 clinical data in ALS; promising preclinical data in other neurodegenerative diseaseALS 30,000 patients (US)450,000 (Worldwide)Progressive MS 500,000 patients (US)1,250,000 (Worldwide)Neurodegenerative disease prevalence expected to increase as population ages3בס"ד

Brainstorm’s Pipeline

Preview truncated — download the full document for the complete content.